The United States Food and Drug Administration issued a voluntary recall on another blood pressure medication. The FDA cited possible contamination.
According to a USA Today report, the blood pressure drug losartan became the latest drug to face a recall due to contamination with a possible cancer-causing agent.
Sandoz Inc. voluntarily recalled losartan potassium hydrochlorothiazide tablets over fears that they may contain N-nitrosodiethylamine (NDEA). NDEA is listed as a possible carcinogen for humans and has led to recalls of the medications irbesartan and valsartan earlier this year.
So far, the latest hypertension drug recall only includes losartan 100 milligram/25 milligram tablets with a lot number of JB8912 that went into distribution on October 8 and later. Patients who have these pills should discuss the situation with their doctor or pharmacist before abruptly stopping them due to health complications. Consumers who have tablets outside of these doses and lot numbers are not included.
CNN reported that NDEA is a stabilizer used in the gasoline industry as a lubricant additive. Zhejiang Huahai Pharmaceutical Company Co. Ltd. manufactured the ingredient, and the company found its way onto an FDA import alert in late September after a facility inspection. Because of that alert, none of its products will be allowed to enter the United States.